SCHEMBL30765713

SCHEMBL30765713

CC(Nc1cnc(N2CCCCC2)n(CC(=O)O)c1=O)c1coc(-c2ccccc2F)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 6/20 0.36
AKT2 P31751 6/20 0.36
AKT3 Q9Y243 6/20 0.36
ALDH1A1 P00352 5/20 0.34
IDH1 O75874 2/20 0.33
TP53 P04637 1/20 0.33
PIK3CA P42336 2/20 0.32
MAOB P27338 1/20 0.32
NPSR1 Q6W5P4 2/20 0.32
PLA2G1B P04054 1/20 0.32
ATG4B Q9Y4P1 1/20 0.32
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
DPP4 P27487 1/20 0.32
PDK1 Q15118 1/20 0.32
PDK2 Q15119 1/20 0.32
PDK3 Q15120 1/20 0.32
PDK4 Q16654 1/20 0.32
LMNA P02545 2/20 0.31
TSHR P16473 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765827 1.00 AKT1 (0.36) AKT1AKT2AKT3ALDH1A1IDH1
SCHEMBL30766059 0.90 ALDH1A1 (0.33) AKT1AKT2AKT3ALDH1A1IDH1
SCHEMBL30765616 0.88 LMNA (0.37) AKT1AKT2AKT3ALDH1A1TP53
SCHEMBL30765781 0.83 F2 (0.33) TSHR
SCHEMBL30765552 0.82 LMNA (0.38) ALDH1A1PIK3CADPP4LMNAKDM4E
SCHEMBL30765747 0.81 ELANE (0.39) ALDH1A1KDM4EMAPT
SCHEMBL30765486 0.80 NTRK1 (0.33) ALDH1A1
SCHEMBL30765445 0.79 AKT1 (0.37) AKT1AKT2AKT3ALDH1A1IDH1
SCHEMBL30766001 0.77 AKT1 (0.36) AKT1AKT2AKT3ALDH1A1IDH1
SCHEMBL30765622 0.73 IDH1 (0.38) AKT1AKT2AKT3ALDH1A1IDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed